随着新的内分泌药物的出现，乳腺癌的内分泌治疗也取得了新的进展。
The endocrine therapy for breast cancer has made progress with the development of new endocrine drugs.
随着新的内分泌药物的出现，乳腺癌的内分泌治疗也取得了新的进展。
The endocrine therapy for breast cancer has made progress with the development of new endocrine drugs.
随着新的内分泌治疗药物的不断研发，激素受体阳性乳腺癌的内分泌治疗疗效逐渐提高。
As new drugs of endocrine therapy are found and used, the effect of endocrine therapy for hormone receptor positive breast cancer is more and more increased.
此外，在ER+/PR+（雌激素受体阳性/孕激素受体阳性）恶性肿瘤和接受阿那曲唑作为内分泌治疗的患者中，发现了（大豆异黄酮和绝经妇女乳腺癌复发率之间）相反的关联。
Additionally, inverse associations were found in those who wee diagnosed with ER+/PR+ malignancy and those who receiving anastrozole as endocrine therapy.
对晚期的乳腺癌患者，经过化疗和内分泌治疗后，5年生存率仍可达到25%以上。
To the later period breast cancer patient, after passing through the chemotherapy and the endocrine treatment, 5 year survival rate still might achieve above 25%.
背景化疗和内分泌治疗在乳腺癌内科治疗中有重要的价值。
BACKGROUNDChemotherapy and incretion treatment play a key role in the treatment of breast cancer.
到目前为止，手术、放疗、化疗、内分泌治疗已并列成为乳腺癌确有疗效的四大治疗手段。
So far, the surgery, the radiotherapy, the chemotherapy, the endocrine treatment compound have become breast cancer to really have the curative effect four big treatment method.
内分泌治疗的远期影响仍然是一个问题，这是因为乳腺癌存活者的人数以及辅助治疗的持续时间都在增长。
The long-term impact of these endocrine manipulations is an issue, because the duration of adjuvant treatment is still increasing, as is the number of breast cancer survivors.
选择性COX - 2抑制剂可联合化疗、内分泌治疗及生物治疗等，作为肿瘤治疗的辅助药物应用于临床，为乳腺癌的治疗提供一种新的途径。
Selective COX-2 inhibitors can combine with chemotherapy, endocrine therapy and biotherapy. It is gradually used for adjunctive therapy and provides a new pathway for the therapy of breast cancer.
作者认为，HD—MA和HD—HPC作为第二线内分泌治疗手段，对于晚期、复发或难治性乳腺癌是安全、有效并有其独具的优点的。
In conclusion, HD-MA and HD-HPC have established a role as, second-line endocrine therapy or salvage measurement for the postmenopausal women with advanced, relapsed and refractory breast cancer.
内分泌治疗是激素受体阳性乳腺癌综合治疗的重要组成部分，其疗效已得到广泛的认可。
Endocrine therapy with certain effect is an important part of combined therapy for hormone receptor-positive breast cancer.
结论术前新辅助内分泌治疗在高龄乳腺癌患者中能达到原发病灶和区域淋巴结降期的目的。
Conclusion Preoperative endocrine therapy for breast cancer of elderly women could effectively delay or remit the advancement of the tumor.
术前辅以新辅助化疗，术后辅以正规内分泌治疗是提高局部晚期乳腺癌生存率的必要手段。
The neoadjuvant chemotherapy and regular endocrine therapy are the necessary measures to improve the survival rates of locally advanced breast cancer.
结论年龄并不是乳腺癌根治术的禁忌，且老年患者从辅助内分泌治疗中获益较多。
Conclusion Age is not the taboo of radical mastectomy, and elderly patients benefit from adjuvant endocrine therapy for more.
目的探讨术前新辅助内分泌治疗在老年乳腺癌治疗中的意义。
Objective To study the curative effect of preoperative endocrine therapy on breast cancer in elderly women.
这些结果表明，AR可为预测ER阳性乳腺癌内分泌疗效的附加指标，以及ER阴性肿瘤靶向治疗的候选靶点。
These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.
这些结果表明，AR可为预测ER阳性乳腺癌内分泌疗效的附加指标，以及ER阴性肿瘤靶向治疗的候选靶点。
These results suggest that AR could be an additional marker for endocrine responsiveness in ER-positive cancers and a candidate for therapeutic targeting of ER-negative tumors.
应用推荐